Cerus Corporation 10-Q Summary
Business context and reporting period
Cerus Corporation develops and commercializes the INTERCEPT Blood System for pathogen reduction in blood components. The platelet and plasma systems were marketed internationally, while the red blood cell system remained in development. This Form 10-Q covers the three and six months ended June 30, 2014, compared with the corresponding 2013 periods.
The FDA had accepted the plasma and platelet premarket approval applications for substantive review. Cerus was also conducting European Phase III trials and a U.S. Phase II study for the red blood cell system.
Key financial metrics
| Metric | Three months ended June 30 | Six months ended June 30 | ||
|---|---|---|---|---|
| 2014 | 2013 | 2014 | 2013 | |
| Revenue | $8.6 million | $10.2 million | $16.5 million | $19.9 million |
| Gross profit | $3.8 million | $4.4 million | $7.6 million | $9.0 million |
| Gross margin | 44.8% | 43.4% | 45.9% | 45.5% |
| Operating loss | $(11.0) million | $(7.1) million | $(20.2) million | $(12.1) million |
| Net loss | $(7.6) million | $(6.7) million | $(7.8) million | $(17.0) million |
| Basic loss per share | $(0.10) | $(0.10) | $(0.11) | $(0.26) |
| Cash flow from operations | Not separately provided | Not separately provided | $(19.4) million | $(14.0) million |
Gross margins improved modestly, but operating losses widened because operating expenses increased substantially. Research and development expense rose 35% in the quarter and 51% year to date, while selling, general and administrative expense rose 27% and 24%, respectively.
At June 30, 2014, cash and cash equivalents were $28.6 million and short-term investments were $21.1 million, for approximately $49.7 million of cash and short-term investments. Total current assets were $70.3 million, compared with current liabilities of $21.7 million. Working capital was approximately $48.6 million.
Total debt was $9.8 million, consisting of a $10.0 million Oxford Finance term loan net of discount. The prior $3.4 million Comerica revolving credit balance was repaid in May 2014. Total contractual obligations were $21.4 million, including $13.0 million of scheduled principal and interest payments, $5.8 million of minimum purchase commitments and $1.4 million of operating leases.
Material changes versus the prior comparable period
- Revenue declined 15% in the second quarter and 17% for the first six months, primarily due to lower disposable-kit and illuminator sales to distributors during territory transitions.
- Gross margin increased to approximately 45% in the quarter and 46% year to date, aided by favorable overhead absorption and lower scrap charges, partly offset by inventory obsolescence charges.
- Operating loss increased by $3.9 million in the quarter and $8.2 million year to date, reflecting higher research and development and selling, general and administrative spending.
- Research and development spending increased primarily because of red blood cell clinical trials and FDA approval activities for the platelet and plasma systems.
- Net loss improved year to date largely because 2014 included a $12.5 million non-cash gain from warrant revaluation, compared with a $4.4 million non-cash loss in 2013. The second-quarter 2014 warrant revaluation gain was $3.5 million.
- Operating cash use increased to $19.4 million from $14.0 million, while cash and short-term investments declined from approximately $57.7 million at December 31, 2013 to approximately $49.7 million at June 30, 2014.
- Cerus sold approximately 0.9 million shares under its Cantor Fitzgerald at-the-market agreement for $3.9 million of net proceeds during the six months. Approximately $37.6 million remained available under the agreement at June 30, 2014.
Guidance, outlook, commentary, risks and unusual items
- Management expected product revenue to remain relatively flat with 2013 in the near term, with a disproportionate adverse impact in the first half of 2014, as distributor territories transitioned to new partners or direct sales. The southern Europe transition was expected to be completed by the fourth quarter of 2014.
- Management expected research and development and selling, general and administrative expenses to increase as the company pursued FDA approvals, conducted red blood cell trials and prepared for potential U.S. commercialization.
- Management stated that available cash, product sales and access to debt were expected to fund capital requirements for at least the next twelve months, but acknowledged that additional capital would be required for certain longer-term development and regulatory activities, particularly the red blood cell system.
- The Oxford term loan permitted up to $30.0 million in three tranches. Only the first $10.0 million tranche had been drawn. The second tranche depended on FDA approval of either the platelet or plasma system; the third also required achievement of a specified revenue threshold.
- The warrant liability was a significant non-cash and volatile earnings item, declining from $20.4 million at December 31, 2013 to $7.7 million at June 30, 2014. Future changes in Cerus’s stock price and warrant assumptions could materially affect reported earnings.
- Cerus depended heavily on Fresenius for manufacturing and was subject to royalties of 10% of platelet-system sales and 3% of plasma-system sales. It also had minimum purchase commitments and other sole-source supplier exposures.
- A distributor termination agreement required potential repurchases and fees, including up to €3.0 million of payments tied to certain future platelet-system sales through April 1, 2018. These amounts were not included in the contractual-obligations table.
- Principal risks included continued losses and cash burn, the need for additional financing, uncertain FDA approval and clinical-trial outcomes, limited market adoption and reimbursement, distributor transitions, manufacturing and supply-chain dependence, product liability, foreign-exchange exposure, intellectual-property challenges and competition.
- No legal proceedings were reported, and management concluded that disclosure controls and procedures were effective as of June 30, 2014.
Important facts for investors to verify
- Progress, timing and outcome of FDA substantive reviews for the platelet and plasma PMAs, including any deficiency letters or post-marketing study requirements.
- Cash consumption, product revenue recovery and the timing of any additional equity or debt financing.
- Whether distributor transitions improve sales execution or cause further revenue, collection and working-capital pressure.
- Enrollment, results and funding requirements for the European Phase III and U.S. Phase II red blood cell studies.
- Availability of the conditional Oxford Finance tranches and compliance with related covenants and collateral requirements.
- Future changes in the fair value of the warrant liability and their effect on reported net income or loss.
- Fresenius manufacturing capacity, minimum purchase obligations, product quality, inventory expiration and sole-source supplier continuity.
- Potential obligations under the terminated distributor arrangement and the effect of royalties and other manufacturing costs on gross margins.